Table 1.
Classification of cytological results and correlation with histological results. RON: risk of neoplasm; ROM: risk of malignancy.
| Cytopathology | Histopathology | RON | ROM | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Milan System Category | Number of Cases (%) | Number of Cases per Category (%) | Not Performed | Non-Neoplastic | Benign Neoplasm | Malignant | RON (%) | RON per Category (%) | ROM (%) | ROM per Category (%) | |
| Non-Diagnostic (ND) | Pauci-cellular | 55 (16.8) | 84 (25.6) |
24 | 2 | 20 | 9 | 29/31 (93.5) | 38/47 (80.9) |
9/31 (29) | 16/47 (34) |
| Cystic content | 25 (7.6) | 13 | 3 | 6 | 3 | 9/12 (75) | 3/12 (25) | ||||
| Lymphocytes | 4 (1.2) | - | - | - | 4 | 4/4 (100) | 4/4 (100) | ||||
| Non-Neoplastic (NN) | Normal lymph node | 7 (2.1) | 27 (8.2) | 5 | 2 | - | - | 0/9 (0) | 1/9 (11.1) | 0/9 (0) | 0/9 (0) |
| Reactive lymph node/Inflammation | 12 (3.7) | 10 | 2 | - | - | 0/9 (0) | 0/9 (0) | ||||
| Lithiasis/sialadenitis | 1 (0.3) | 1 | - | - | - | 0/9 (0) | 0/9 (0) | ||||
| Cyst | 7 (2.1) | 2 | 4 | 1 | - | 1/9 (11.1) | 0/9 (0) | ||||
| Atypia of Undetermined Significance (AUS) | 4 (1.2) | 4 (1.2) | 2 | - | 2 | - | 2/2 (100) | 2/2 (100) | 0/2 (0) | 0/2 (0) | |
| Benign Neoplasm (BN) | Pleomorphic adenoma | 89 (27.1) | 145 (44.2) |
18 | - | 67 | 4 | 71/71 (100) | 105/105 (100) | 4/71 (5.63) | 4/105 (3.09) |
| Warthin’s tumour | 55 (16.8) | 21 | - | 34 | - | 34/34 (100) | 0/34 (0) | ||||
| Schwanomma | 1 (0.3) | 1 | - | - | - | - | - | ||||
| Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP) | Oncocytic | 7 (2.1) | 15 (4.6) | 3 | 2 | 1 | 1 | 2/4 (50) | 7/11 (63.6) | 1/4 (25) | 5/11 (45.5) |
| Unspecified | 8 (2.4) | 1 | 2 | 1 | 4 | 5/7 (71.4) | 4/7 (57.1) | ||||
| Suspicious for malignancy (SM) | Epithelial | 6 (1.8) | 16 (4.9) | 1 | 2 | 3 | 5/6 (83.3) | 13/16 (81.3) | 3/6 (50) | 11/16 (68.8) |
|
| Lymphoma | 10 (3.1) | - | 2 | - | 8 | 8/10 (80) | 8/10 (80) | ||||
| Malignant (M) | Low-grade | 1 (0.3) | 37 (11.3) |
- | - | - | 1 | 1/1 (100) | 26/26 (100) | 1/1 (100) | 26/26 (100) |
| High-grade | 23 (7) | 4 | - | - | 19 | 19/19 (100) | 19/19 (100) | ||||
| Metastasis | 13 (4) | 7 | - | - | 6 | 6/6 (100) | 6/6 (100) | ||||
| Total | 328 (100) | 328 (100) | 112 (34.2) | 18 (5.5) | 136 (41.5) | 62 (18.9) | - | ||||